ROHTAK NEWS

Rohtak. Kovaxin, India’s first potential vaccine for COVID-19,

Rohtak. Kovaxin, India's first potential vaccine for COVID-19,
Rohtak. Kovaxin, India’s first potential vaccine for COVID-19, has been allowed to undergo human trials for the first and second phases from drug regulator DGCI. Now its trial will be in 12 centers across the country including Rohtak PGI. This vaccine has been prepared by Hyderabad-based pharma company Bharat Biotech.
It has been made jointly by the Indian Council of Medical Research (ICMR) and the National Institute of Virology Pune. Its pre-clinical trials have been successful. Now trials on humans will be started from this month of July.
For this important trial, Dr. Savita Verma, Professor, Department of Pharmacology, PGIMS, Rohtak, has been given the responsibility of Co-Investigator, Principal Investigator, State Nodal Officer of COVID-19, Dr. Dhruv Chaudhary and Dr. Ramesh Verma of Community Department. Dr. Ramesh Verma said that this trial is to be held in 2 phases. 375 will be included in the first phase and 750 volunteers in the second phase. State Nodal Officer of State COVID-19, Dr. Dhruv Chaudhary said that any interested person can register to be a part of the trial by calling PGIMS COVID helpline 9416447071.
If you do not understand my given information,then you can ask me your question in the comment box, I will answer your questions as soon as possible.

Leave a Reply

Your email address will not be published. Required fields are marked *